Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study

Myelodysplastic syndrome (MDS) with TP53 mutations has a poor prognosis after transplantation, and novel therapeutic means are urgently needed. Decitabine (Dec) monotherapy has demonstrated improved overall response rates in MDS and acute myeloid leukaemia, although these responses were not durable....

Full description

Bibliographic Details
Main Authors: Yuxin Wang, Yao Sun, Jing Xie, Jiangwei Hu, Na Liu, Jianlin Chen, Botao Li, Sanchun Lan, Jingwen Niu, Lei Wang, Zhuoqing Qiao, Yu Zhang, Jing Ren, Bin Zhang, Liren Qian, Yehui Tan, Liping Dou, Yuhang Li, Liangding Hu
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-07-01
Series:Frontiers in Oncology
Subjects:
allogeneic haematopoietic stem cell transplantation
TP53 mutation
decitabine
conditioning regimen
myelodysplastic syndrome
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.928324/full

Similar Items

Similar Items